Chester County News and Community Website
Ocugen, Inc. (NASDAQ: OCGN), headquartered in Malvern, PA, is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Their breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and their novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, visit www.ocugen.com.
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has received approval from Health Canada to begin the Phase 3 liMeliGhT clinical trial for their OCU400 gene therapy. This trial aims to …
Ocugen Expands Gene Therapy Trial to Canada Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced its financial results for the second quarter of 2024 and provided a business update.
Ocugen Reports Q2 2024 Financial Results and Business Update Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has received approval from the Food and Drug Administration to begin its expanded access program (EAP) for the treatment of adult patients with …
Ocugen Receives FDA Approval for Expanded Access Program for Retinitis Pigmentosa Treatment Read More MALVERN, PA — Ocugen, Inc. (Nasdaq: OCGN) announced the successful closing of its public offering of 30,434,783 shares of common stock on Friday. Each share was sold at $1.15, generating …
Ocugen Closes $35 Million Public Offering on Friday Read More MALVERN, PA — Ocugen, Inc. (Nasdaq: OCGN) launched a public offering of its common stock on July 31, 2024. The company also plans to grant the underwriter a 30-day option …
Ocugen Announces Public Offering of Common Stock Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) this week announced the completion of dosing in the third cohort of its Phase 1/2 ArMaDa clinical trial for OCU410, a novel gene …
Ocugen Completes Dosing in Phase 1/2 Trial for Gene Therapy to Treat Geographic Atrophy Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) this week announced the progression of its OCU410ST GARDian clinical trial after the Data and Safety Monitoring Board (DSMB) approved moving forward with …
Ocugen Advances Stargardt Disease Therapy with Positive Clinical Trial Progress Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced the first patient has been dosed in its Phase 3 liMeliGhT clinical trial for OCU400, a gene therapy candidate for retinitis pigmentosa …
Ocugen Doses First Patient in Phase 3 Trial for Retinitis Pigmentosa Therapy Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced a positive outcome from the Data and Safety Monitoring Board (DSMB) review of its Phase 1/2 ArMaDa clinical trial for OCU410, a …
Ocugen’s Gene Therapy Shows Promise in Early Trial for Age-Related Macular Degeneration Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced its upcoming inclusion in the Russell 3000® Index, set to take effect after the market closes on June 28, 2024. This announcement …
Ocugen to Join Russell 3000 Index Amid Transformative Year Read More